Posted by Michael Wonder on 06 Aug 2019
Proposals for funding in the immunosuppressant, cardiovascular and anti-nausea therapeutic areas
6 August 2019 - PHARMAC is seeking feedback on proposals for widening access to medicines in the immunosuppressant, cardiovascular and anti-nausea therapeutic areas.
In summary, the proposals would result in the following changes from 1 October 2019:
- Adalimumab (Humira) access would be widened to include treatment of hidradenitis suppurativa, a chronic inflammatory skin condition
- Nicardipine hydrochloride injection access would be widened in DHB hospitals to include use as an antihypertensive/vasodilator in adults
- Ondansetron dispersible tablets would be available on a Practitioner’s Supply Order for treatment of acute nausea and vomiting
